These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
832 related items for PubMed ID: 22332705
21. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Curr Med Res Opin; 2007 Aug; 23(8):1749-59. PubMed ID: 17588306 [Abstract] [Full Text] [Related]
26. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL. Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849 [Abstract] [Full Text] [Related]
29. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients. Thyagarajan V, Norman H, Alexander KA, Napalkov P, Enger C. Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510 [Abstract] [Full Text] [Related]
31. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Finckh A, Simard JF, Gabay C, Guerne PA, SCQM physicians. Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288 [Abstract] [Full Text] [Related]
32. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, Chen L, Beukelman T, Saag KG, Curtis JR. Arthritis Care Res (Hoboken); 2015 May; 67(5):624-32. PubMed ID: 25370912 [Abstract] [Full Text] [Related]
33. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. J Med Econ; 2012 May; 15(2):264-75. PubMed ID: 22115327 [Abstract] [Full Text] [Related]
37. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR, Favalli EG, Erre GL, Gorla R, Galeazzi M, Foti R, Cantini F, Salvarani C, Olivieri I, Lapadula G, Ferraccioli G, Gruppo Italiano di Studio sulle Early Arthritis (GISEA). Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143 [Abstract] [Full Text] [Related]
38. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, Rodríguez-Arboleya L, Navarro-Compán V, Toyos J. Rheumatology (Oxford); 2007 Mar; 46(3):529-32. PubMed ID: 17012439 [Abstract] [Full Text] [Related]
39. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Borah BJ, Huang X, Zarotsky V, Globe D. Curr Med Res Opin; 2009 Jun; 25(6):1365-77. PubMed ID: 19425902 [Abstract] [Full Text] [Related]